P r lichtlen (36 risultati)

hardback. 1991. Adalat A Comprehensive Review. There are many charts, tables and graphs. Nifedipine 237 Very good to fine in a very good dust wrapper.

03. Condizione: Wie neu. 1988. Sprache: Deutsch.

Hardcover. Condizione: Very Good. Condizione sovraccoperta: Very Good. 0387540334. Blue cloth hardcover, from closed pharmaceutical company library, with usual labels, marks. Lending record shows this book has never been borrowed. 237 pages, index, illustrated with charts, tables and diagrams. This volume documents the Adalat story, from its beginnings in research and development to its pioneering role in new areas of pharmacological treatment. Adalat is effective in treating hypertension, acute neurology, dementia, atherosclerosis and heart failure. This book surveys a chapter in the history of cardiovascular research. Sections include: Adalat History; Hypertension; Coronory Heart Disease; Coronory Atherosclerosis; Outlook, Adalat: Its Future. Contents appears unread, clean, tight and bright. Book.…

Edited by P. R. Lichtlen / H.-J. Engel / A. Schrey / H. J. C. Swan. Nitrates III. Cardiovascular effects. Springer-Verlag. Berlin/Heidelberg/New York 1981. XX, 597 S. mit 326 Tabellen und Illustrationen. Original-Ganzleinen mit Rücken- und Deckeltitel nebst Original-Schutzumschlag mit Innentext. Zustand: Von sehr guter Erhaltung. Ungelesen. Keine Remittende. [SW: Nitrates, Pharmacodynamics + Kinetics, Hemodynamics, Coronary Flow, Perfusion, Vascular Effects, Pulmonary Circulation, Myocordail Infarction, Angina, Exercise, Heart Failure, Bypass Surgery, Valvular Heart Disease] Sprache: en 1322 Gramm. …

Paper bound, illustrated w/graphs & tables, xviii + Pp568. Includes indices. As new. 1.1 kilograms - extra postage will be requested for all international shipments outside Canada and the USA.

Condizione: Gut. Gr-8vo. 193 S. OKt. Einband leicht berieben, Stempel auf Titelseiten, Besitzvermerk auf Vorsatz, sonst gut erhalten.

Gr.-8°, Leinen. Condizione: Gut. 662 S., mit 326 Abb. Gebraucht: SU. leicht berieben, ansonsten sehr guter Zustand. Aus dem Inhalt: Grundlagen der Nitratwirkungen / Pharmakodynamik und -kinetik / Hämodynamik / Koronarfluß und Myokarddruchblutung / Gefäßwirkungen / Lungenkreislauf / Akuter Moykardinfarkt udn instabile Angina pectoris / Belastung / Chonische Herzinsuffizienz / Bypass-Operationen; Herzklappenfehler / Poster Session. Sprache: Deutsch Gewicht in Gramm: 1391.…

Condizione: New. In English.

Condizione: New.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.…

Condizione: New. pp. 260.

Paperback. Condizione: Brand New. reprint edition. 252 pages. 9.25x6.10x0.62 inches. In Stock.

Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Softcover. Condizione: Sehr gut. 123 Dieses Buch bietet praxisorientierte Leitlinien zur Anwendung von Kalzium-Antagonisten in der Medizin. Es enthält Ergebnisse von Expertengesprächen und behandelt die therapeutischen und pharmazeutischen Aspekte dieser Arzneimittelklasse. Zustand: Einband mit stärkeren Gebrauchsspuren, Seiten geringfügig gebräunt, insgesamt GUTER Zustand. HC1-412-4/8-00709631 Sprache: Deutsch Gewicht in Gramm: 123.…

hardcover. 597 S. LN. mit SU., Orig cloth with dust jacket , sehr guter Zustand, very best condition, ENGLISCH. Sprache: Deutsch Gewicht in Gramm: 1400.

Paperback. Condizione: New.

M. 64 Tab. u. 168 Abb. IX, 293 S. Sprache: Deutsch 0 gr.

Condizione: New. In English.

Condizione: New. pp. 684.

Paperback. Condizione: Brand New. reprint edition. 682 pages. German language. 9.60x6.69x1.34 inches. In Stock.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - In vielen pharmakologischen Instituten und kardiologischen Kliniken werden in zunehmendem Umfang Nitrate experimentell und klinisch untersucht. Dies ist iiberraschend, wenn man bedenkt, daB bereits vor iiber hundert Jahren Brunton und Murrell im Lancet iiber die giinstige Wirkung dieser Substanzen bei der Angina pectoris berichtet haben. Seit den beiden vorausgegangenen Nitrat-Symposien, in Stockholm 1975 und Berlin 1978, sind - wie erwartet - eine Menge neuer Erkenntnisse gewonnen worden. Dieses Wissen betraf Pharmakologie, Pharmakokinetik und Pharmako dynamik der Nitrate, besonders aber auch ihre klinischen Wirkungen bei akuter und chronischer Ischamie des Herzens und bei schwerer dekompensierter Herz insuffizienz. Daran gemessen war der Fortschritt bei der Erforschung des moleku laren Wirkungsmechanismus der Nitrate eher bescheiden. Obwohl die meisten U ntersucher iibereinstimmen, daB Anderungen von intrazellularem Calcium wahrscheinlich der Hauptwirkungsmechanismus sind, durch welchen Nitrate zu einer Abnahme des Tonus glatter GefaBmuskulatur fiihren. Der genaue art ihrer Wirkung ist noch unbekannt. 1m Gegensatz dazu sind die dosisabhangigen Unterschiede der Wirkungen auf das venose und arteriolare GefaBsystem seit langem gut bekannt. Die Behandlung mit Nitraten stand erneut im Mittelpunkt der Diskussionen. Ausfiihrlich wurde die Frage der Entwicklung einer Toleranz nach Langzeit Therapie mit Nitraten diskutiert. Dabei wurde der Ausdruck 'Pseudo-Toleranz' zur Beschreibung der Anpassung des Kreislaufsystems an die chronische Vasodila tation verwendet. Diese chronische Vasodilatation ist fiir die Langzeit-Prophylaxe sowohl bei stabiler als auch bei instabiler Angina pectoris (d. h. bei Zustanden mit erhohtem Vasomotorentonus-Spasmus) von besonderer Bedeutung. Unter der wissenschaftlichen Leitung von P. R. LICHTLEN hat 1980 das III.…

Condizione: New.

Hard Cover. Condizione: Good. [Por]. (Eds.). Springer-Verlag. Berlin. 1991.De 24x16 cm. Com 237, [ii] págs. Encadernação do editor. Ilustrado no texto com gráficos, desenhos e fotografias a cores e a preto e branco. Language: Inglês / English Location/localizacao: SACO RS705-06.

Paperback. Condizione: Very Good. Dust Jacket may NOT BE INCLUDED.CDs may be missing. SHIPS FROM MULTIPLE LOCATIONS. book.

Condizione: Bueno. 420. Tapa blanda. SPRINGER VERLAG IBÉRICA. 1991, 420pp.

Condizione: new. Questo è un articolo print on demand.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge. 260 pp. Englisch.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 260 pp. Englisch.…

Condizione: New. Print on Demand pp. 260 67 Figures.

Condizione: New. PRINT ON DEMAND pp. 260.